CTLA4 and systemic lupus erythematosus: Relatedly, the in vitro treatment of splenocytes from lupus-prone BXSB mice with OX40L mAb, in combination with an anti-CTLA-4 strategy, suppresses autoantibody production and pro-inflammatory cytokines [52].